MMP26: A potential biomarker for prostate cancer

Abstract

The application of prostate-specific antigen (PSA) in the screening and diagnosis of prostate cancer (PCa) has improved the clinical management of PCa patients. However, the PSA assay has been faced with criticism due to its potential association with over-diagnosis and subsequent overtreatment of indolent patients. Matrix metalloproteinase-26 (MMP26) is a member of matrix metalloproteinases (MMPs) and has been reported to be highly expressed in many cancers. This investigation evaluated the potential of serum MMP26 as a biomarker for PCa. The level of serum MMP26 was measured by enzyme-linked immunosorbent assay (ELISA) in 160 subjects including PCa group (n=80), benign prostatic hyperplasia (BPH) group (n=40) and control group (n=40). Furthermore, we evaluated the expression of MMP26 in tissues by immunohistochemistry. The results showed the serum MMP26 levels were significantly higher in PCa group than in BPH group and control group. Similarly, the MMP26 protein was positive in PCa tissues and negative in BPH tissues and control tissues. In conclusion, these results suggested MMP26 could be used as a potential serum biomarker in the diagnosis of PCa.

<p>Matrilysins and Stromelysins in Pathogenesis and Diagnostics of Cancers</p>

“…Summarizing, MMP-26 may be used as a diagnostic biomarker for identifying PCa patients from benign prostate hyperplasia patients and healthy individuals. 49 …”

Identification of key genes in prostate cancer gene expression profile by bioinformatics

“…In recent years, many investigations concentrated on finding variant biomarkers in the prostate carcinogenesis progression. For example, matrix metalloproteinase‐26 and tumour necrosis factor receptor‐associated factor 2 have been identified (Cheng et al, ; Wei et al, ). Despite great progress has been made, the molecular mechanism of prostate cancer is far from being completely explained.…”

Matrix Metalloproteinase 26 (Mmp-26) Overexpression in Prostatic Adenocarcinoma

“…Serum PSA is measured for early detection, staging, and monitoring of the disease. However, it might have low specificity when the values range between 3 and 10 ng/ml, and also showing an increase in benign conditions such as BHP and prostatitis 2,16 . The search for new biomarkers, which combined with PSA can provide greater precision in the diagnosis, has led to several studies on the expression of MMP, both in serum and in tissue samples of PC.…”

“…Recently, the prognostic value of MMP-26 has been evaluated in colorectal cancer, where significant expression was associated with invasion, metastasis, and lower overall patient survival 15 . MMP-26 was also significantly higher in both serum and tissue of patients with PC 16 . Despite this, there are fewer studies devoted to the MMP-26 and PC.…”